Market Overview

UPDATE: Credit Suisse Downgrades Johnson & Johnson to Underperform on Valuation

Share:
Related JNJ
Benzinga's M&A Chatter for Wednesday February 25, 2015
Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'
Some Companies Are More Wonderful Than Others (Seeking Alpha)

Credit Suisse downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Underperform and raised the price target from $71.00 to $73.00.

Credit Suisse commented, "Concurrent with Credit Suisse rating methodology requiring that ratings now reflect an expectation of relative out/(under) performance versus an analyst's coverage universe, we downgrade JNJ to Underperform from Neutral. While we advocate overweight positions in pharma stocks and acknowledge the stock's "index importance", JNJ offers the lowest total return in our coverage universe (dividend plus equity), hence this change. Along with adjustments to target price to other stocks in our sector, we raise JNJ's target to $73 from $71, below its current level of $75."

Johnson & Johnson closed at $75.39 on Wednesday.

Latest Ratings for JNJ

DateFirmActionFromTo
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Downgrades Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→